ImportRefusal LogoImportRefusal

USV Private Limited

⚠️ High Risk

FEI: 3003255171 • Govandi, Mumbai • INDIA

FEI

FEI Number

3003255171

📍

Location

Govandi, Mumbai

🇮🇳

Country

INDIA
🏢

Address

Redg. Office: B.S.D. Marg, B-249, 250, 147 & 148, Peenya 2nd Stage, Govandi, Mumbai, India

High Risk

FDA Import Risk Assessment

70.7
LowModerateHighCritical

This firm has a significant history of FDA import refusals with notable violations.

Statistics

42
Total Refusals
8
Unique Violations
6/20/2025
Latest Refusal
11/1/2005
Earliest Refusal

Score Breakdown

Violation Severity
81.6×40%
Refusal Volume
60.5×30%
Recency
88.8×20%
Frequency
21.4×10%
How is this score calculated?

Proprietary Algorithm

  • 40% Violation Severity — AI-assessed (1-10)
  • 30% Refusal Volume — Logarithmic scale
  • 20% Recency — Decays over 5 years
  • 10% Frequency — Refusals per year

© ImportRefusal.com Original Analysis

Violation Summary

7539×

UNAPPROVED

The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a new drug within the meaning of Section 201(p) without an approved New Drug Application (NDA).

1184×

NOT LISTED

It appears the drug or device is not included in a list required by Section 510(j), or a notice or other information respecting it was not provided as required by section 510(j) or 510(k).

22801×

DIRSEXMPT

The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a drug within the meaning of Section 201(g) and it lacks adequate directions for use.

32801×

FRNMFGREG

The article is subject to refusal of admission pursuant to section 801(a)(3) in that it appears to be misbranded as defined in section 502(o) of the FD&C Act. It appears that it was manufactured, prepared, propagated, compounded, or processed in an establishment not duly registered under section 510 of the Act.

35001×

RXLABEL

The labeling fails to bear, at a minimum, the symbol "RX Only".

37411×

FRNMFGREG

The article is subject to refusal of admission pursuant to section 801(o) in that it is being imported or offered for import into the United States, and the importer, owner, or consignee of such article did not, at the time of offering the article for import, submit to the Secretary a statement that identifies the registration under section 510(i) of the Act of each establishment that with respect to such article is required under such section to register with the Secretary.

4821×

NUTRIT LBL

The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be misbranded in that the label or labeling fails to bear the required nutrition information.

1791×

AGR RX

The article appears to be a prescription drug manufactured in the U.S. and offered for import by other than the manufacturer and reimportation does not appear to have been authorized by the Secretary for use in a medical emergency.

Refusal History

DateProductViolationsDivision
6/20/2025
60LCY05ASPIRIN (ANALGESIC)
75UNAPPROVED
Division of Southeast Imports (DSEI)
6/16/2025
61PCY26METFORMIN (ANTI-DIABETIC)
2280DIRSEXMPT
3500RXLABEL
Division of Northeast Imports (DNEI)
6/11/2025
61PDY09GLIPIZIDE (ANTI-DIABETIC)
75UNAPPROVED
Division of Southeast Imports (DSEI)
1/21/2025
60LCY05ASPIRIN (ANALGESIC)
75UNAPPROVED
Division of Southeast Imports (DSEI)
12/12/2024
62CCC99ANTI-HYPERTENSIVE N.E.C.
75UNAPPROVED
Division of Southeast Imports (DSEI)
9/11/2024
61PCY99ANTI-DIABETIC N.E.C.
75UNAPPROVED
Division of Southeast Imports (DSEI)
8/21/2024
60LCY05ASPIRIN (ANALGESIC)
118NOT LISTED
3280FRNMFGREG
75UNAPPROVED
Division of Northeast Imports (DNEI)
8/8/2024
60QDJ07LIDOCAINE
75UNAPPROVED
Division of Southeast Imports (DSEI)
5/22/2024
61PDA09GLIPIZIDE (ANTI-DIABETIC)
75UNAPPROVED
Division of Southeast Imports (DSEI)
4/3/2024
66VDY99MISCELLANEOUS PATENT MEDICINES, ETC.
118NOT LISTED
75UNAPPROVED
Division of Southeast Imports (DSEI)
8/18/2023
60LDY05ASPIRIN (ANALGESIC)
75UNAPPROVED
Division of Southeast Imports (DSEI)
1/6/2022
61JDA08ATORVASTATIN CALCIUM (ANTI-CHOLESTEREMIC)
75UNAPPROVED
Division of Southeast Imports (DSEI)
12/29/2021
62OCY09TELMISARTAN (ANTI-HYPERTENSIVE - PART II)
75UNAPPROVED
Division of Southeast Imports (DSEI)
12/29/2021
61PDY09GLIPIZIDE (ANTI-DIABETIC)
75UNAPPROVED
Division of Southeast Imports (DSEI)
7/22/2021
61PDA26METFORMIN (ANTI-DIABETIC)
75UNAPPROVED
Division of Southeast Imports (DSEI)
7/22/2021
61PDA26METFORMIN (ANTI-DIABETIC)
75UNAPPROVED
Division of Southeast Imports (DSEI)
7/22/2021
61PDA26METFORMIN (ANTI-DIABETIC)
75UNAPPROVED
Division of Southeast Imports (DSEI)
7/22/2021
61LDA03ANISINDIONE (ANTI-COAGULANT)
75UNAPPROVED
Division of Southeast Imports (DSEI)
7/7/2021
60LCC05ASPIRIN (ANALGESIC)
75UNAPPROVED
Division of Southeast Imports (DSEI)
7/7/2021
62OCC09TELMISARTAN (ANTI-HYPERTENSIVE - PART II)
75UNAPPROVED
Division of Southeast Imports (DSEI)
3/23/2021
60LDA05ASPIRIN (ANALGESIC)
75UNAPPROVED
Division of Southeast Imports (DSEI)
12/11/2018
60LIA05ASPIRIN (ANALGESIC)
75UNAPPROVED
Division of Southeast Imports (DSEI)
4/30/2018
62CCA68OLMESARTAN MEDOXOMIL
75UNAPPROVED
Division of Southeast Imports (DSEI)
11/3/2017
66SCY28NITROGLYCERIN (TAB) (VASODILATOR)
75UNAPPROVED
Division of Southeast Imports (DSEI)
10/27/2017
61PCA26METFORMIN (ANTI-DIABETIC)
75UNAPPROVED
Division of Southeast Imports (DSEI)
7/26/2017
62OCC14AMLODIPINE BESYLATE (ANTI-HYPERTENSIVE, PART II)
75UNAPPROVED
Division of Southeast Imports (DSEI)
3/1/2017
66VCY99MISCELLANEOUS PATENT MEDICINES, ETC.
75UNAPPROVED
Division of Southeast Imports (DSEI)
10/7/2016
61PCB26METFORMIN (ANTI-DIABETIC)
75UNAPPROVED
New Orleans District Office (NOL-DO)
10/7/2016
60LDB05ASPIRIN (ANALGESIC)
75UNAPPROVED
New Orleans District Office (NOL-DO)
9/9/2016
62OCA09TELMISARTAN (ANTI-HYPERTENSIVE - PART II)
75UNAPPROVED
Division of Northern Border Imports (DNBI)
1/5/2016
66VCY99MISCELLANEOUS PATENT MEDICINES, ETC.
75UNAPPROVED
Cincinnati District Office (CIN-DO)
1/5/2016
60LCY05ASPIRIN (ANALGESIC)
75UNAPPROVED
Cincinnati District Office (CIN-DO)
5/26/2015
61PDY26METFORMIN (ANTI-DIABETIC)
75UNAPPROVED
Cincinnati District Office (CIN-DO)
9/27/2013
61PDB11GLYBURIDE (ANTI-DIABETIC)
118NOT LISTED
3741FRNMFGREG
75UNAPPROVED
New Orleans District Office (NOL-DO)
6/11/2012
60LCB05ASPIRIN (ANALGESIC)
75UNAPPROVED
New Orleans District Office (NOL-DO)
2/20/2008
54ACY99VITAMIN, N.E.C.
482NUTRIT LBL
New Orleans District Office (NOL-DO)
2/20/2008
66VBY99MISCELLANEOUS PATENT MEDICINES, ETC.
75UNAPPROVED
New Orleans District Office (NOL-DO)
10/18/2007
61PBA55METFORMIN HCL (ANTI-DIABETIC)
75UNAPPROVED
New Orleans District Office (NOL-DO)
4/26/2007
61JDB09FENOFIBRATE (ANTI-CHOLESTEREMIC)
75UNAPPROVED
New Orleans District Office (NOL-DO)
5/31/2006
62NIS03ACITRETIN (ANTI-PSORIATIC)
118NOT LISTED
75UNAPPROVED
New York District Office (NYK-DO)
11/1/2005
61PCA55METFORMIN HCL (ANTI-DIABETIC)
179AGR RX
New Orleans District Office (NOL-DO)
11/1/2005
61PCA09GLIPIZIDE (ANTI-DIABETIC)
75UNAPPROVED
New Orleans District Office (NOL-DO)

Frequently Asked Questions

What is USV Private Limited's FDA import refusal history?

USV Private Limited (FEI: 3003255171) has 42 FDA import refusal record(s) in our database, spanning from 11/1/2005 to 6/20/2025.

What is an FEI number?

FEI stands for Firm Establishment Identifier. It's a unique number assigned by the FDA to identify establishments that manufacture, process, pack, or hold food, drugs, medical devices, or other FDA-regulated products. USV Private Limited's FEI number is 3003255171.

What types of violations has USV Private Limited received?

USV Private Limited has been cited for 8 different violation type(s). Common FDA violations include adulteration (unsafe or unsanitary products), misbranding (incorrect or misleading labels), and regulatory non-compliance.

Where does this information about USV Private Limited come from?

All FDA import refusal data for USV Private Limited is sourced from the official FDA Data Dashboard (datadashboard.fda.gov), a public government database maintained by the U.S. Food and Drug Administration.

Data sourced from the FDA Data Dashboard, a public database maintained by the U.S. Food and Drug Administration.